Search
Cardiolipin Biosynthesis CL(8:0/10:0/10:0/i-15:0)
smpdb.ca/view/SMP0226139MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Cardiolipin Biosynthesis CL(8:0/10:0/10:0/i-17:0)
smpdb.ca/view/SMP0226141MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Cardiolipin Biosynthesis CL(8:0/10:0/10:0/i-20:0)
smpdb.ca/view/SMP0226144MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Cardiolipin Biosynthesis CL(8:0/10:0/10:0/i-21:0)
smpdb.ca/view/SMP0226145MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Dexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. … release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.
Mixtures: DUEDOM 30/10 MG KAPSÜL, 30 ADET, DUEDOM 60/10 MG KAPSÜL, 30 ADETCategories: Heterocyclic Compounds, 1-Ring, Drugs for Acid Related DisordersIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[L49776,L49781] The FDA approval was based on positive results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom … [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.
Products: İKTU 30 MG/3 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, FIRAZYR 30 MG/3 ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnThe therapy is intended to cure or achieve a sustained virologic response (SVR12), after 12 weeks of daily therapy. … Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.
Categories: Heterocyclic Compounds, 1-Ring, Antivirals for Systemic UseProducts: DASVIR 30 (DACLATASVIR TABLETS 30 MG), DASVIR 60 (DACLATASVIR TABLETS 60 MG)Dulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: TRULICITY® 1.5 MG/0.5 ML, TRULICITY® 0.75 MG/0.5 MLAbatacept
go.drugbank.com/drugs/DB01281ApprovedInvestigationalAlthough approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077). … [L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each
Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: ORENCIA® SOLUCION INYECTABLE PARA ADMINISTRACION SUBCUTÁNEA 125 MG/ML, ORENCIA 250 MG KON.PERFUZYONLUK COZ.ICIN TOZ ICEREN FLAKONCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of … Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding
Mixtures: CEFAZIME FOR INJECTION 1 g/vial, ZAVİCEFTA 2 G/0.5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 10 ADETCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use